Beneficial and adverse effects of molecularly targeted therapies for acute promyelocytic leukemia in central nervous system

CNS and Neurological Disorders - Drug Targets

Volumn 8, Issue 5, 2009, Pages 387-392

  Nagai, Sumimasa ^a   Takahashi, Tsuyoshi ^a   Kurokawa, Mineo ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Acute promyelocytic leukemia; Alltrans retinoic acid; Arsenic trioxide; Central nervous system; Gemtuzumab ozogamicin; Pseudotumor cerebri; Relapse; Subarachnoid hemorrhage; Targeted therapy

Indexed keywords

ARSENIC TRIOXIDE; GEMTUZUMAB OZOGAMICIN; HYBRID PROTEIN; PROMYELOCYTIC LEUKEMIA PROTEIN; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; ANTINEOPLASTIC AGENT; ORGANOARSENIC DERIVATIVE; OXIDE;

CANCER CHEMOTHERAPY; CENTRAL NERVOUS SYSTEM LEUKEMIA; DRUG MECHANISM; DRUG TARGETING; HUMAN; LEUKEMIA RELAPSE; NONHUMAN; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; REVIEW; CENTRAL NERVOUS SYSTEM TUMOR; METABOLISM; RECURRENT DISEASE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARSENICALS; CENTRAL NERVOUS SYSTEM NEOPLASMS; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; OXIDES; RECURRENCE; TRETINOIN;

EID: 73949133131     PISSN: 18715273     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152709789541943     Document Type: Review

References (46)

1. Wang, Z.Y.; Chen, Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood, 2008, 111, 2505-2515.
2. Sanz, M.A.; Grimwade, D.; Tallman, M.S.; Lowenberg, B.; Fenaux, P.; Estey, E.H.; Naoe, T.; Lengfelder, E.; Büchner, T.; Döhner, H.; Burnett, A.K.; Lo-Coco, F. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood, 2009, 113, 1875-1891.
3. de Botton, S.; Sanz, M.A.; Chevret, S.; Dombret, H.; Martin, G.; Thomas, X.; Mediavilla, J.D.; Recher, C.; Ades, L.; Quesnel, B.; Brault, P.; Fey, M.; Wandt, H.; Machover, D.; Guerci, A.; Maloisel, F.; Stoppa, A.M.; Rayon, C.; Ribera, J.M.; Chomienne, C.; Degos, L.; Fenaux, P.; European APL Group; PETHEMA Group. Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Leukemia, 2006, 20, 35-41.
4. Raanani, P.; Shpilberg, O.; Ben-Bassat, I. Extramedullary disease and targeted therapies for hematological malignancies-is the association real? Ann. Oncol., 2007, 18, 7-12.
5. Zhu, J.; Chen, Z.; Lallemand-Breitenbach, V.; de The, H. How acute promyelocytic leukaemia revived arsenic. Nat. Rev. Cancer, 2002, 2, 705-713.
6. Lallemand-Breitenbach, V.; Zhu, J.; Kogan, S.; Chen, Z.; de The, H. Opinion: how patients have benefited from mouse models of acute promyelocytic leukaemia. Nat. Rev. Cancer, 2005, 5, 821-827.
7. Nasr, R.; Guillemin, M.C.; Ferhi, O.; Soilihi, H.; Peres, L.; Berthier, C.; Rousselot, P.; Robledo-Sarmiento, M.; Lallemand-Breitenbach, V.; Gourmel, B.; Vitoux, D.; Pandolfi, P.P.; Rochette-Egly, C.; Zhu, J.; de The, H. Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. Nat. Med., 2008, 14, 1333-1342.
8. Villa, R.; Pasini, D.; Gutierrez, A.; Morey, L.; Occhionorelli, M.; Viré, E.; Nomdedeu, J.F.; Jenuwein, T.; Pelicci, P.G.; Minucci, S.; Fuks, F.; Helin, K.; Di Croce, L. Role of the polycomb repressive complex 2 in acute promyelocytic leukemia. Cancer Cell, 2007, 11, 513-525.
9. Miller, W.H.; Jr.; Schipper, H.M.; Lee, J.S.; Singer, J.; Waxman, S. Mechanisms of action of arsenic trioxide. Cancer Res., 2002, 6, 3893-3903.
10. Petrie, K.; Zelent, A. Marked for death. Nat. Cell Biol., 2008, 10, 507-509.
11. Tatham, M.H.; Geoffroy, M.C.; Shen, L.; Plechanovova, A.; Hattersley, N.; Jaffray, E.G.; Palvimo, J.J.; Hay, R.T. RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nat. Cell Biol., 2008, 10, 538-546.
12. Lallemand-Breitenbach, V.; Jeanne, M.; Benhenda, S.; Nasr, R.; Lei, M.; Peres, L.; Zhou, J.; Zhu, J.; Raught, B.; de The, H. Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat. Cell Biol., 2008, 10, 547-555.
13. Tallman, M.S.; Altman, J.K. Curative strategies in acute promyelocytic leukemia. Hematol. Am. Soc. Hematol. Educ. Progr., 2008, 391-399.
14. Kogan, S.C. Curing APL: differentiation or destruction? Cancer Cell, 2009, 15, 7-8.
15. Lo-Coco, F.; Cimino, G.; Breccia, M.; Noguera, N.I.; Diverio, D.; Finolezzi, E.; Pogliani, E.M.; Di Bona, E.; Micalizzi, C.; Kropp, M.; Venditti, A.; Tafuri, A.; Mandelli, F. Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood, 2004, 104, 1995-1999.
16. Lo Coco, F.; Ammatuna, E.; Noguera, N. Treatment of acute promyelocytic leukemia with gemtuzumab ozogamicin. Clin. Adv. Hematol. Oncol., 2006, 4, 57-62.
17. Tsimberidou, A.M.; Estey, E.; Whitman, G.J.; Dryden, M.J.; Ratnam, S.; Pierce, S.; Faderl, S.; Giles, F.; Kantarjian, H.M.; Garcia-Manero, G. Extramedullary relapse in a patient with acute promyelocytic leukemia: successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies. Leuk. Res., 2004, 28, 991-994.
18. Lunghi, M.; Castagnola, C.; Calatroni, S.; Bernasconi, P.; Lazzarino, M. Central nervous system relapse in acute promyelocytic leukaemia. Haematologica, 2006, 91, ECR24.
19. Specchia, G.; Lo Coco, F.; Vignetti, M.; Avvisati, G.; Fazi, P.; Albano, F.; Di Raimondo, F.; Martino, B.; Ferrara, F.; Selleri, C.; Liso, V.; Mandelli, F. Extramedullary involvement at relapse in acute promyelocytic leukemia patients treated or not with all-trans retinoic acid: a report by the Gruppo Italiano Malattie Ematologiche dell'Adulto. J. Clin. Oncol., 2001, 19, 4023-4028.
20. Evans, G.; Grimwade, D.; Prentice, H.G.; Simpson, N. Central nervous system relapse in acute promyelocytic leukaemia in patients treated with all-trans retinoic acid. Br. J. Haematol., 1997, 98, 437-439.
21. Ko, B.S.; Tang, J.L.; Chen, Y.C.; Yao, M.; Wang, C.H.; Shen, M.C.; Tien, H.F. Extramedullary relapse after all-trans retinoic acid treatment in acute promyelocytic leukemia-the occurrence of retinoic acid syndrome is a risk factor. Leukemia, 1999, 13, 1406-1408.
22. Breccia, M.; Carmosino, I.; Diverio, D.; De Santis, S.; De Propris, M.S.; Romano, A.; Petti, M.C.; Mandelli, F.; Lo-Coco, F. Early detection of meningeal localization in acute promyelocytic leukaemia patients with high presenting leucocyte count. Br. J. Haematol., 2003, 120, 266-270.
23. Ades, L.; Chevret, S.; Raffoux, E.; de Botton, S.; Guerci, A.; Pigneux, A.; Stoppa, A.M.; Lamy, T.; Rigal-Huguet, F.; Vekhoff, A.; Meyer-Monard, S.; Maloisel, F.; Deconinck, E.; Ferrant, A.; Thomas, X.; Fegueux, N.; Chomienne, C.; Dombret, H.; Degos, L.; Fenaux, P.; European Acute Promyelocytic Leukemia Group. Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group. J. Clin. Oncol., 2006, 24, 5703-5710.
24. Asou, N.; Kishimoto, Y.; Kiyoi, H.; Okada, M.; Kawai, Y.; Tsuzuki, M.; Horikawa, K.; Matsuda, M.; Shinagawa, K.; Kobayashi, T.; Ohtake, S.; Nishimura, M.; Takahashi, M.; Yagasaki, F.; Takeshita, A.; Kimura, Y.; Iwanaga, M.; Naoe, T.; Ohno, R.; Japan Adult Leukemia Study Group. A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARalpha transcript after consolidation therapy: the Japan Adult Leukemia Study Group (JALSG) APL97 study. Blood, 2007, 110, 59-66.
25. Kaspers, G.; Gibson, B.; Grimwade, D.; Pession, A.; Smith, O.; Testi, A.M. Central nervous system involvement in relapsed acute promyelocytic leukemia. Pediatr. Blood Cancer, 2009, [Epub ahead of print].
26. Quijano, S.; López, A.; Manuel, S.J.; Panizo, C.; Debén, G.; Castilla, C.; Antonio García-Vela, J.; Salar, A.; Alonso-Vence, N.; González-Barca, E.; Peñalver, F.J.; Plaza-Villa, J.; Morado, M.; García-Marco, J.; Arias, J.; Briones, J.; Ferrer, S.; Capote, J.; Nicolás, C.; Orfao, A.; Spanish Group for the Study of CNS Disease in NHL. Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin's lymphoma: improved sensitivity of flow cytometry. J. Clin. Oncol., 2009, 27,1462-1469.
27. Patriarca, F.; Fili, C.; Geromin, A.; Sperotto, A.; Prosdocimo, S.; Fanin, R. Activity of all-trans-retinoic acid in a case of central nervous system extramedullary relapse of acute promyelocytic leukemia. Eur. J. Haematol., 2002, 68, 310-313.
28. Bae, S.H.; Ryoo, H.M.; Cho, H.S.; Lee, J.L.; Lee, K.H.; Hyun, M.S. Meningeal relapse in a patient with acute promyelocytic leukemia: a case report and review of the literature. J. Korean Med. Sci., 2004, 19, 311-314.
29. Nagai, S.; Asai, T.; Watanabe, T.; Oshima, K.; Hangaishi, A.; Kanda, Y.; Motokura, T.; Chiba, S.; Aoki, S.; Ohtomo, K.; Kurokawa, M. Simultaneous appearance of central nervous system relapse and subarachnoid hemorrhage during the treatment for acute promyelocytic leukemia. Ann. Hematol., 2008, 87, 593-595.
30. Owonikoko, T.; Agha, M.; Balassanian, R.; Smith, R.; Raptis, A. Gemtuzumab therapy for isolated extramedullary AML relapse following allogeneic stem-cell transplant. Nat. Clin. Pract. Oncol., 2007, 4, 491-495.
31. Piccaluga, P.P.; Martinelli, G.; Rondoni, M.; Malagola, M.; Gaitani, S.; Isidori, A.; Bonini, A.; Gugliotta, L.; Luppi, M.; Morselli, M.; Sparaventi, G.; Visani, G.; Baccarani, M. Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas. Leuk. Lymphoma, 2004, 45, 1791-1795.
32. Au, W.Y.; Ma, S.K.; Ooi, C.; Liang, R.; Kwong, Y.L. Unusual manifestations of acute leukemia. Case 1. CNS extramedullary relapse of acute promyelocytic leukemia after arsenic trioxide-induced remission. J. Clin. Oncol., 2000, 18, 3435-3437.
33. Mathews, V.; Balasubramanian, P.; Shaji, R.V.; George, B.; Chandy, M.; Srivastava, A. Central nervous system relapse in a patient with acute promyelocytic leukaemia treated with arsenic trioxide. Br. J. Haematol., 2001, 113, 257-258.
34. Au, W.Y.; Tam, S.; Fong, B.M.; Kwong, Y.L. Elemental arsenic entered the cerebrospinal fluid during oral arsenic trioxide treatment of meningeal relapse of acute promyelocytic leukemia. Blood, 2006, 107, 3012-3013.
35. Knipp, S.; Gattermann, N.; Schapira, M.; Käferstein, H.; Germing, U. Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement. Leuk. Res., 2007, 31, 1585-1587.
36. Helwig, A.; Klemm, M.; Schuttig, R.; Rollig, C.; Wassilew, N.; Ehninger, G.; Illmer, T. Arsenic-induced APL differentiation in cerebrospinal fluid. Leuk. Res., 2007, 31, 703-705.
37. Au, W.Y.; Tam, S.; Fong, B.M.; Kwong, Y.L. Determinants of cerebrospinal fluid arsenic concentration in patients with acute promyelocytic leukemia on oral arsenic trioxide therapy. Blood, 2008, 112, 3587-3590.
38. Au, W.Y.; Tam, S.; Kwong, Y.L. Entry of elemental arsenic into the central nervous system in patients with acute promyelocytic leukemia during arsenic trioxide treatment. Leuk. Res., 2008, 32, 357-358.
39. Falanga, A.; Barbui, T. Coagulopathy of acute promyelocytic leukemia. Acta Haematol., 2001, 106, 43-51.
40. Jin, Z.; Ran, M.; Man, Z. Arsenic trioxide entered cerebrospinal fluid with the help of mannitol overwhelm the meningeal relapse of acute promyelocytic leukemia. Haematologica, 2007, 92, e82-e84.
41. Tse, E.; Yip, S.F.; Ooi, C.G.; Kwong, Y.L. Subarachnoid haemorrhage: more than meets the eye. Br. J. Haematol., 2006, 132, 383.
42. Mitchell. P.; Wilkinson, I.D.; Hoggard, N.; Paley, M.N.; Jellinek, D.A.; Powell, T.; Romanowski, C.; Hodgson, T.; Griffiths, P.D. Detection of subarachnoid haemorrhage with magnetic resonance imaging. J. Neurol. Neurosurg. Psychiatry, 2001, 70, 205-211.
43. Roberts, T.F.; Sprague, K.; Schenkein, D.; Miller, K.B.; Relias, V. Hyperleukocytosis during induction therapy with arsenic trioxide for relapsed acute promyelocytic leukemia associated with central nervous system infarction. Blood, 2000, 96, 4000-4001.
44. Parma, M.; Casaroli, I.; Pogliani, E.M. Occurrence of cerebellar thrombohemorrhage during all-trans retinoic acid (ATRA) therapy in a case of acute promyelocytic leukemia. Haematologica, 1996, 81, 379-380.
45. Machner, B.; Neppert, B.; Paulsen, M.; Hofmann, C.; Sander, T.; Helmchen, C. Pseudotumor cerebri as a reversible side effect of all-trans retinoic acid treatment in acute promyelocytic leukaemia. Eur. J. Neurol., 2008, 15, e68-e69.
46. Sanz, M.A.; Tallman, M.S.; Lo-Coco, F. Tricks of the trade for the appropriate management of newly diagnosed acute promyelocytic leukemia. Blood, 2005, 105, 3019-3025.